{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:59:10Z","timestamp":1787900350396,"version":"build-2784847793"},"reference-count":57,"publisher":"American Society of Consultant Pharmacists","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2009,7,1]]},"DOI":"10.4140\/tcp.n.2009.524","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T02:14:40Z","timestamp":1294884880000},"page":"524-537","source":"Crossref","is-referenced-by-count":23,"title":["Treatment of Chorea Associated with Huntington's Disease: Focus on Tetrabenazine"],"prefix":"10.4140","volume":"24","author":[{"given":"Stephen M.","family":"Setter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Neumiller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K.","family":"Dobbins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina A. K.","family":"DuVall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Santiago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2625","published-online":{"date-parts":[[2009,10,2]]},"reference":[{"key":"1","first-page":"320","article-title":"On chorea","volume":"XXVI","author":"G Huntington","year":"1872","journal-title":"The Medical and Surgical Reporter"},{"key":"2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/brain\/awg077","article-title":"Homozygosity for CAG mutation in Huntington disease associated with a more severe clinical course","volume":"126","author":"F Squitieri","year":"2003","journal-title":"Brain"},{"key":"3","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","article-title":"The sensitivity and specificity of measuring CAG repeats","volume":"330","author":"B Kremer","year":"1994","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.49.4.1048","article-title":"US Huntington Disease Genetic Testing Group. Genetic testing of children at risk for Huntington's disease","volume":"49","author":"M Nance","year":"1997","journal-title":"Neurology"},{"key":"5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/78054","article-title":"Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity","volume":"25","author":"H Li","year":"2000","journal-title":"Nat Genet"},{"key":"6","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1093\/hmg\/ddn218","article-title":"Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via ubiquitin-proteasome system-dependent mechanism","volume":"20","author":"H Wong","year":"2008","journal-title":"Hum Mol Genet"},{"key":"7","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.1523\/JNEUROSCI.3237-08.2008","article-title":"Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25\/ cyclin-dependent kinase 5","volume":"40","author":"P Paoletti","year":"2008","journal-title":"J Neurosci"},{"key":"8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.arcmed.2007.11.011","article-title":"Excitotoxic neuronal death and the pathogenesis of Huntington's disease","volume":"39","author":"A Estrada S\u00e1nchez","year":"2008","journal-title":"Arch Med Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/brain\/awf179","article-title":"The distribution of structural neuropathology in pre-clinical Huntington's disease","volume":"125","author":"M Thieben","year":"2002","journal-title":"Brain"},{"key":"10","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1212\/01.WNL.0000065888.88988.6E","article-title":"Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis","volume":"60","author":"H Rosas","year":"2003","journal-title":"Neurology"},{"key":"11","first-page":"215","article-title":"Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease","volume":"47","author":"A Ciarmiello","year":"2006","journal-title":"J Nucl Med"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Politis M, Pavese N, Tai YF et al. Hypothalamic involvement in Huntington's disease: an <i>in vivo<\/i> PET study. Brain 2008 (epub ahead of print - October 1).","DOI":"10.1093\/brain\/awn244"},{"key":"13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/B978-0-443-07941-2.50018-8","volume-title":"Huntington disease. In: Principles and Practice of Movement Disorders","author":"SF Fahn","year":"2007"},{"key":"14","first-page":"359","article-title":"Huntington's disease: pathogenesis, diagnosis and treatment","volume":"19","author":"S Purdon","year":"1994","journal-title":"J Psychiatr Neurosci"},{"key":"15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/archneur.58.2.273","article-title":"Progression of symptoms in the early and middle stages of Huntington disease","volume":"58","author":"S Kirkwood","year":"2001","journal-title":"Arch Neurol"},{"key":"16","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/01.WNL.0000086373.32347.16","article-title":"Huntington's disease: clinical correlates of disability and progression","volume":"61","author":"N Mahant","year":"2003","journal-title":"Neurology"},{"key":"17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's disease rating scale: reliability and consistency","volume":"11","year":"1996","journal-title":"Mov Disord"},{"key":"18","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awg119","article-title":"Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study","volume":"126","author":"N Pavese","year":"2003","journal-title":"Brain"},{"key":"19","first-page":"219","article-title":"Behavioral changes in Huntington disease","volume":"14","author":"D Craufurd","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"20","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1212\/01.WNL.0000052992.58107.67","article-title":"Predictors of nursing home placement in Huntington disease","volume":"60","author":"V Wheelock","year":"2003","journal-title":"Neurology"},{"key":"21","first-page":"193","article-title":"Psychiatric features of Huntington's disease: recent approaches and findings","volume":"1","author":"S Folstein","year":"1983","journal-title":"Psychiatr Dev"},{"key":"22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ajmg.1320240211","article-title":"Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk","volume":"24","author":"L Farrer","year":"1986","journal-title":"Am J Med Genet"},{"key":"23","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/302388","article-title":"Outrageous fortune: the risk of suicide in genetic testing for Huntington disease","volume":"64","author":"T Bird","year":"1999","journal-title":"Am J Hum Genet"},{"key":"24","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/jmg.29.12.911","article-title":"Causes of death in patients with Huntington's disease and in unaffected first degree relatives","volume":"29","author":"S S\u00f8rensen","year":"1992","journal-title":"J Med Genet"},{"key":"25","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/brain\/119.5.1633","article-title":"Executive and mneumonic functions in early Huntington's disease","volume":"119","author":"A Lawrence","year":"1996","journal-title":"Brain"},{"key":"26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/01376517-198904000-00005","article-title":"Dysphagia in Huntington's disease","volume":"21","author":"V Hunt","year":"1989","journal-title":"J Neurosci Nur"},{"key":"27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archneur.1985.04060010063017","article-title":"Dysphagia in Huntington's disease","volume":"42","author":"N Leopold","year":"1985","journal-title":"Arch Neurol"},{"key":"28","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington's disease: an evidence-based review","volume":"12","author":"R Bonelli","year":"2006","journal-title":"Curr Pharm Des"},{"key":"29","volume-title":"Xenazine [package insert]","year":"2008"},{"key":"30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/14737175.6.1.7","article-title":"Tetrabenazine in the treatment of hyperkinetic movement disorders","volume":"6","author":"C Kenney","year":"2006","journal-title":"Expert Rev Neurother"},{"key":"31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/WNF.0b013e3180ca77ea","article-title":"A study of chorea after tetrabenazine withdrawal in patients with Huntington disease","volume":"31","author":"S Frank","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"32","first-page":"250","article-title":"Bioavailability and dose dependency studies","volume":"15","author":"R Mehavar","year":"1987","journal-title":"Drug Met Disp"},{"key":"33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00002826-200211000-00003","article-title":"Tetrabenazine treatment for Huntington's disease-associated chorea","volume":"25","author":"W Ondo","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mds.10427","article-title":"Tetrabenazine in the treatment of severe pediatric chorea","volume":"18","author":"A Chatterjee","year":"2003","journal-title":"Mov Disord"},{"key":"36","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1136\/bmj.1.6073.1391-a","article-title":"Tetrabenazine in Sydenham's chorea","volume":"1","author":"C Hawkes","year":"1977","journal-title":"Br Med J"},{"key":"37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1469-8749.1974.tb02733.x","article-title":"Tetrabenazine in athetoid cerebral palsy","volume":"16","author":"H Heggarty","year":"1974","journal-title":"Develop Med Child Neurol"},{"key":"38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1212\/WNL.38.3.391","article-title":"Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias","volume":"38","author":"J Jankovic","year":"1988","journal-title":"Neurology"},{"key":"39","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.31.8.1051","article-title":"Tetrabenazine and movement disorders","volume":"31","author":"S Asher","year":"1981","journal-title":"Neurology"},{"key":"40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.410110108","article-title":"Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study","volume":"11","author":"J Jankovic","year":"1982","journal-title":"Ann Neurol"},{"key":"41","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/archneur.1974.00490410100014","article-title":"Spontaneous oral dyskinesia: results of treatment with tetrabenazine, pimozide, or both","volume":"31","author":"H Pakkenberg","year":"1974","journal-title":"Arch Neurol"},{"key":"42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.1972.01750250081011","article-title":"Clinical efficacy of a dopamine-depleting agent, tetrabenazine","volume":"27","author":"H Kazamatsuri","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"43","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/ajp.130.4.479","article-title":"Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine","volume":"130","author":"H Kazamatsuri","year":"1973","journal-title":"Am J Psychiatry"},{"key":"44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bmj.4.5778.25","article-title":"Persistent phenothiazine dyskinesia treated with tetrabenazine","volume":"4","author":"R Godwin-Austen","year":"1971","journal-title":"Br Med J"},{"key":"45","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archpsyc.1974.01760180095012","article-title":"Presynaptic catecholamine antagonists as treatment for Tourette syndrome","volume":"31","author":"R Sweet","year":"1974","journal-title":"Arch Gen Psychiatry"},{"key":"46","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00002826-198212000-00005","article-title":"Alphamethylparatyrosine and tetrabenazine in movement disorders","volume":"5","author":"A Lang","year":"1982","journal-title":"Clin Neuropharmacol"},{"key":"47","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ana.410130406","article-title":"Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients","volume":"13","author":"J Jankovic","year":"1983","journal-title":"Ann Neurol"},{"key":"48","first-page":"515","article-title":"Tetrabenazine in the treatment of hyperkinetic movement disorders","volume":"225","author":"J Jankovic","year":"1983","journal-title":"Adv Neurol"},{"key":"49","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00002826-200111000-00002","article-title":"Dyskinesia: L-dopa-induced and tardive dyskinesia","volume":"24","author":"O Rascol","year":"2001","journal-title":"Clin Neuropharm"},{"key":"50","unstructured":"50. Prestwick Pharmaceuticals. Tetrabenazine: briefing document for peripheral and central nervous system advisory committee. Available at http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4328b1-02-Prestwick.pdf. Accessed September 9, 2008. <a target=\"_blank\" href='http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4328b1-02-Prestwick.pdf.'>http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4328b1-02-Prestwick.pdf.<\/a>"},{"key":"51","unstructured":"51. Micromedex Healthcare Series. Thomson Micromedex Online. Available at http:www.thomsonhc.com. Accessed October 10, 2008. <a target=\"_blank\" href='http:www.thomsonhc.com.'>www.thomsonhc.com.<\/a>"},{"key":"52","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/mds.870120219","article-title":"A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment","volume":"12","author":"G Petzinger","year":"1997","journal-title":"Mov Disord"},{"key":"53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.870110118","article-title":"Tetrabenazine as a cause of neuroleptic malignant syndrome","volume":"11","author":"M Ossemann","year":"1996","journal-title":"Mov Disord"},{"key":"54","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/WNL.31.8.1022","article-title":"Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease","volume":"31","author":"R Burke","year":"1981","journal-title":"Neurology"},{"key":"55","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00002826-199202000-00009","article-title":"Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease","volume":"15","author":"D Mateo","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"56","unstructured":"56. Clinical Pharmacology Online. Available at http:\/\/clinicalpharmacology. com. Accessed October 10, 2008. <a target=\"_blank\" href='http:\/\/clinicalpharmacology.'>http:\/\/clinicalpharmacology.<\/a>"},{"key":"57","unstructured":"57. Lexi-Comp Online. Available at http:\/\/online.lexi.com.Accessed October 10, 2008. <a target=\"_blank\" href='http:\/\/online.lexi.com.Accessed'>http:\/\/online.lexi.com.Accessed<\/a>"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T17:25:30Z","timestamp":1740849930000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2009\/00000024\/00000007\/art00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,1]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7,1]]}},"alternative-id":["1V14NH4H31350355"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2009.524","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7,1]]}}}